drugset / Trial / NCT05050604
A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate in Vascular Cognitive Impairment Patients
Phase 4
Unknown
418 enrolled
Chong Kun Dang Pharmaceutical
Choline Alfoscerate Re-evaluation Consortium (57 pharmaceutical companies) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a multi-center, randomized, double-blind, placebo-controlled, Phase IV Trial to evaluate the efficacy and safety of Choline Alfoscerate compared to placebo in Mild Cognitive Impairment Patients with Cerebrovascular Disease
Timeline
- Start
- 2021-09
- Primary completion
- 2024-11
- Completion
- 2024-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Choline Alfoscerate | Unknown | 400 mg | Oral |